Get the Stockscreener App
0.00
100.00%
-8.28
Cybin Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$8.28
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$413.12M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
0.00
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$9.83
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
0.00 | 413.12M | 0 | -52.07M | -44.93M | -0.2077 |
VRTX
Vertex Pharmaceuticals Inc
|
439.63 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
764.19 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.99 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
314.83 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
302.10 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | TD Cowen | Buy |
| Feb-02-26 | Initiated | Jefferies | Buy |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Robert Langer, who helped found Moderna, joins Helus Pharma board - Stock Titan
How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative - simplywall.st
[SCHEDULE 13G/A] CYBIN INC. Amended Passive Investment Disclosure - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade) (NASDAQ:HELP) - Seeking Alpha
Trump's Executive Order May Boost Psychedelic Stocks. Here Are 7 to Buy in 2026 - U.S. News Money
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN
Helus Pharma CEO Michael Cola steps down at board’s request By Investing.com - Investing.com India
Helus Pharma CEO Michael Cola steps down; Eric So takes interim CEO role - MSN
Helus Pharma Backs U.S. Executive Order Accelerating Psychedelic Treatment Pathways - TipRanks
Helus Pharma (Nasdaq: CYBN) aligns late-stage NSA pipeline with U.S. psychedelic policy push - Stock Titan
Helus Pharma (CYBN) CEO steps down as co-founder Eric So becomes interim chief - Stock Titan
Psychedelic Stocks Surge After Executive Order, Focus on Compass Pathways (CMPS) - GuruFocus
Helus Pharma CEO Michael Cola steps down at board’s request - Investing.com
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions - The Manila Times
White House psychedelics push intersects with Helus Phase 3 depression drug - Stock Titan
Helus Pharma Announces CEO Changes Effective April 20, 2026 - marketscreener.com
Cybin Inc. Common Stock (HELP) - Minichart
Cybin Insider Ups Holding By 105% During Year - Yahoo Finance
HELP Options Chain — NASDAQ:HELP - TradingView
Millennium Management LLC Acquires Additional Shares in Helus Ph - GuruFocus
Psychedelic Stocks Tracker - Psychedelic Alpha
Helus Pharma (Nasdaq: HELP; CYBN) taps Dr. Ken Kramer to lead medical - Stock Titan
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs - Investing News Network
Helus Pharma Taps Neuroscience Veteran Ken Kramer to Lead Medical Affairs - TipRanks
Cybin Inc (HELP) reports positive phase 2 anxiety study data - MSN
HELP Initiated Coverage by TD Cowen -- Price Target Set at $8 - GuruFocus
Cybin Inc. (NASDAQ:HELP) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Aug PostEarnings: What hedge funds are buying Cybin Inc2026 Historical Comparison & Daily Chart Pattern Signals - baoquankhu1.vn
Cybin (NASDAQ:HELP) Now Covered by TD Cowen - MarketBeat
Top Cybin (HELP) Competitors 2026 - MarketBeat
HELP: Cybin Inc.Brokerage Recommendations Chart - Zacks Investment Research
Helus Pharma (HELP) Stock Analysis Report | Financials & Insights - Benzinga
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - ADVFN
Millennium Group (CYBN) reports 2.51M shares, 5.0% stake - Stock Titan
Rate Cut: Will Cybin Inc stock recover after earningsRisk Management & Technical Pattern Based Signals - baoquankhu1.vn
Can Cybin (HELP) Stock Beat Estimates | Price at $5.33, Up 1.52%Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai
Aug Decliners: Does Cybin Inc stock have upside surprise potential2026 Short Interest & Weekly Breakout Watchlists - baoquankhu1.vn
Total non-current assets of Cybin, Inc. – NEO:HELP - TradingView — Track All Markets
Cybin Inc (NASDAQ:HELP) - intelligentinvestor.com.au
HELP Should I Buy - Intellectia AI
HELP Stock Price, Quote & Chart | CYBIN INC (NASDAQ:HELP) - ChartMill
Trend Recap: Is Cybin Inc on track to beat earningsTrade Entry Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Guidance Update: Can Cybin Inc be the next market leader2026 Analyst Calls & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.34%
0.80%
Cap:
|
Volume (24h):